View Whole Prescribing Info OPDIVO® (nivolumab) is indicated to the treatment of adult patients with classical Hodgkin lymphoma (cHL) which has relapsed or progressed after autologous hematopoietic stem mobile transplantation (HSCT) and brentuximab vedotin or soon after 3 or more strains of systemic therapy that features autologous HSCT.The compan